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Immediate drug hypersensitivity reactions (DHRs) resemble typical immunoglobulin
E (IgE)-mediated symptoms. Clinical manifestations range from local skin reactions,
gastrointestinal and/or respiratory symptoms to severe systemic involvement with
potential fatal outcome. Depending on the substance group of the eliciting drug
the correct diagnosis is a major challenge. Skin testing and in vitro diagnostics
are often unreliable and not reproducible. The involvement of drug-specific IgE is
questionable in many cases. The culprit substance (parent drug or metabolite) and
potential cross-reacting compounds are difficult to identify, patient history and drug
provocation testing often remain the only means for diagnosis. Hence, several groups
proposed basophil activation test (BAT) for the diagnosis of immediate DHRs as basophils
are well-known effector cells in allergic reactions. However, the usefulness of BAT in
immediate DHRs is highly variable and dependent on the drug itself plus its capacity
to spontaneously conjugate to serum proteins. Stimulation with pure solutions of the
parent drug or metabolites thereof vs. drug-protein conjugates may influence sensitivity
and specificity of the test. We thus, reviewed the available literature about the use
of BAT for diagnosing immediate DHRs against drug classes such as antibiotics,
radio contrast media, neuromuscular blocking agents, non-steroidal anti-inflammatory
drugs, and biologicals. Influencing factors like the selection of stimulants or of the
identification and activation markers, the stimulation protocol, gating strategies, and cut-
off definition are addressed in this overview on BAT performance. The overall aim is to
evaluate the suitability of BAT as biomarker for the diagnosis of immediate drug-induced
hypersensitivity reactions.
Keywords: antibiotics, basophil activation test, biologicals, chemotherapeutics, fluoroquinolones, NMBAs,
NSAIDs, RCM
KEY PLAYERS IN THE IMMEDIATE-TYPE ALLERGIC EFFECTOR
PHASE
Key characteristic of allergic effector cells in immediate-type allergy is allergen-specific IgE bound
to the high affinity IgE receptor, i.e., FcεRI, on the cell surface. Capturing of allergens by surface
IgE results in FcεRI crosslinking and elicits the acute phase of the allergic response involving the
sudden release of vasoactive mediators into the tissue and/or circulation. This sudden activation
process and mediator release is termed anaphylactic degranulation (depicted in Figure 1A) and
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may induce life-threatening anaphylaxis (Hoffmann, 2015). Mast
cells and basophils both share these key characteristics. Mast
cells reside in the tissue and are considered primary allergic
effector cells. Basophils are peripheral blood granulocytes, easily
accessible via venipuncture and a well-established surrogate for
allergy diagnosis (MacGlashan, 2013).
THE BASOPHIL ACTIVATION TEST
Basophil activation can be measured by flow cytometry and
multicolor staining with fluorescent-labeled detection antibodies
targeting specific identification and activation markers on
the surface of basophils. The most common identification
strategies use surface IgE, eotaxin CC chemokine receptor
3 (CCR3), the combination of interleukin 3 receptor alpha
chain CD123high with human leukocyte antigen HLA-DRneg,
the combination of prostaglandin D2 receptor CRTH-2
high with
CD3neg, or the basophil-specific ectonuclease CD203c. Table 1
provides an overview of basophil identification strategies in
drug hypersensitivity research which we numbered “strategy
1” through “strategy 6” according to the frequency they have
been used. For basophil activation the degranulation marker
lysosomal-associated membrane glycoprotein-3 (LAMP-3), also
termed CD63, or upregulation of CD203c are determined. Thus,
changes in activation state can be quantified on a single cell basis.
Degranulation means fusion of specific intracellular vesicles
filled with preformed mediators, the so-called granules, with the
plasma membrane and a transition of CD63 from inside out.
The result is a sudden and pronounced rise, i.e., log-shift, of the
fluorescence intensity signal, in the detection of surface CD63.
Concomitantly, upregulation of CD203c has been observed
which can be detected as significant increase in the mean
fluorescence intensity signal of the CD203c detection antibody.
Flow cytometry dot plots for both activation scenarios are
depicted in Figure 1B. For further details about assay parameters
of BAT the interested reader is referred to the comprehensive
review of McGowan and Saini (2013).
In addition to anaphylactic degranulation another type of
basophil activation termed piecemeal degranulation has been
described (Dvorak, 2005). This alternative activation mechanism
may also lead to altered surface expression of activation
markers which can be assessed by BAT (Hausmann et al., 2009;
MacGlashan, 2010). Consequently, BAT has been recognized
as a promising tool for in vitro diagnosis of allergy or other
hypersensitivity reactions including immediate adverse reactions
to various drugs (Hoffmann et al., 2015).
TECHNICAL ISSUES OF BASOPHIL
ACTIVATION TESTING
Usually BAT is performed from either heparinized, citrate-
or EDTA-anticoagulated whole blood collected from
allergic/hypersensitive donors (Table 1). When EDTA is
used as anticoagulant Ca++ has to be supplemented to enable
proper degranulation. For in vitro stimulation of basophils the
samples are incubated with the allergen/drug or buffer only
(negative control) for several minutes to hours at 37◦C. As
positive control, anti-IgE antibodies, anti-FcεRI antibodies,
and formyl-methionine-leucine-phenylalanine (fMLF) are
used. Latter represents an alternative degranulation/activation
stimulus and is important to demonstrate basophil functionality
in case of donors whose basophils fail to react in vitro to
IgE-mediated pathway stimulation, so-called non-responders
(Eberlein et al., 2010; MacGlashan, 2013).
Next, basophil identification and activation markers are
stained with fluorescently labeled antibodies, subsequently
erythrocytes are lysed. Depending on the protocol, staining can
be performed during basophil stimulation in a single step. Upon
flow cytometric acquisition of at least 200, in the optimal case
500–1000 basophils, activation marker expression is compared
between buffer-treated samples and allergen-/drug-stimulated
basophils. Different evaluation strategies are used. Some studies
set the cut-off for spontaneously activated basophils arbitrarily at
5%, whereas others use stimulation indices of %CD63-/CD203c-
positive cells, i.e., SI(%), or mean fluorescence intensities (MFI)
of activation markers, i.e., SI, compared to negative control
(Table 1). For interpretation of BAT area under the dose curve
(AUC) measurements have recently been postulated. These
enable a combined evaluation of basophil reactivity, i.e., the
dose (range) at which maximal response occurs, and basophil
sensitivity, i.e., the dose at which half of the maximal response
occurs. As the AUC representation incorporates partial energy,
which may arise at high allergen concentrations, and can be
calculated even in cases where responses do not fit the typical
shape of dose–response curves, it is particularly useful for
monitoring the efficacy in allergen-specific immunotherapy (Ebo
et al., 2004; Hausmann et al., 2009; Hoffmann et al., 2015).
BASOPHIL ACTIVATION TEST WITH
DRUGS—BACKGROUND
CONSIDERATIONS
Small molecular weight drugs constitute haptens which are not
capable of FcεRI crosslinking themselves (hapten concept; Pichler
et al., 2011). They require conjugation to carrier molecules
(Figure 1A), usually abundant blood proteins, for eliciting an
immune reaction in susceptible individuals. Moreover, reactive
intermediates may be formed by drug metabolism (pro-hapten
concept; Park et al., 1998; Naisbitt et al., 2000). Therefore, the
use of drug metabolites and hapten-carrier conjugates has been
promoted for the investigation of drug hypersensitivity reactions
(Himly et al., 2003; Harrer et al., 2010; Steiner et al., 2011,
2014). Of note, in a case of propyphenazone (PP) hypersensitivity
basophils reacted in BAT solely upon stimulation with the drug-
carrier conjugate but not with pure PP (Steiner et al., 2014).
Nevertheless, BAT is most frequently performed with solutions
of plain drugs, a consequence of lacking knowledge in regard
to relevant determinants, metabolic intermediates, their reactive
functions, required linker length to the carrier molecule, and
hapten orientation.
Alternative to the hapten and pro-hapten concepts in DHRs,
the p-i concept has become well-accepted, however, it primarily
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FIGURE 1 | (A) Schematic illustration of IgE-mediated cross-linking. Upon binding of the hapten-carrier complex to the drug-specific IgE captured on high affinity IgE
receptor FcεRI, basophils react by degranulation and mediator release. CD63 is transferred from the vesicle to the plasma membrane and CD203c is upregulated,
thus both serve as activation markers. (B) Flow cytometry dot plots of typical activation patterns for CD63 and CD203c; CCR3, basophil identification marker; PE,
phycoerthrin label; FITC, fluorescein label; PE-Dy647, tandem label.
accounts for T cell-mediated delayed-type immune reactions
against drugs such as lidocaine, sulfamethoxazole, lamotrigine,
carbamazepine, p-phenylendiamine, etc. or against metals like in
nickel contact dermatitis (Pichler et al., 2006). DHRs of this kind
are elicited on a different time-scale, not discussed here, and an
involvement of basophils is unlikely. A comprehensive overview
can be gained from reviews by Pichler et al. (Pichler, 2003; Pichler
et al., 2015).
BAT FOR THE EVALUATION OF
IMMEDIATE DRUG HYPERSENSITIVITY TO
DIFFERENT DRUG CLASSES
In the following paragraphs the suitability of basophil activation
as a biomarker for evaluating immediate hypersensitivity
reactions to different drug classes is discussed. The assay
parameters used and activation patterns observed in the cited
studies are summarized in Table 1.
Basophil Activation in Antibiotics or
Quinolone Hypersensitivity
Immediate DHRs against beta-lactam antibiotics such as
penicillin, amoxicillin, and cephalosporin have been broadly
investigated and are most likely IgE-mediated. Diagnosis of beta-
lactam allergy first place is based on skin prick and intradermal
tests. Sensitivity of skin tests, however, does not exceed 50–
70%. The in vitro diagnostic method of quantifying beta-lactam-
specific IgE antibodies (Mangodt et al., 2015) is an important
complementary information. Clinically validated tests for drug-
specific IgE, however, are difficult to develop, require complex
coupling reactions for attaching the drug hapten onto a solid
phase for antibody recognition, and are available only for a
limited number of antibiotics. Instead, simple drug dilutions
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are used in BAT. It thus, appears a promising tool for in vitro
diagnosis of beta-lactam allergy. Several groups investigated the
applicability of BAT in the diagnostic management of beta-
lactam allergy (Sanz et al., 2002; Gamboa et al., 2004a; Torres
et al., 2004, 2010a, 2011; Abuaf et al., 2008; De Week et al.,
2009; Eberlein et al., 2010; Garcia-Ortega and Marin, 2010). BAT
performance, however, varied between groups with a median
sensitivity of 50% (range 22–55%) and specificity ranging from 79
to 100%. Quintessence of these studies is that BAT was superior
to immunoassaying for drug-specific IgE, but not to skin testing.
Importantly, skin testing and BAT do not necessarily corroborate
each other. Positive skin testing has been confirmed by BAT
only in about 50–60% of patients (De Week et al., 2009; Torres
et al., 2010a), whereas up to one third of skin test-negative
patients have been identified by BAT (De Week et al., 2009). The
tenor across studies thus was that the role of BAT currently is
complementary, respectively supplementary, in the diagnosis of
beta–lactam allergy.
Factors possibly contributing to the observed variance
in sensitivity of BAT may involve patients selection criteria
such as severity of reactions and time elapsed since the
reaction (optimum: 1–6 months), regional preferences in drug
prescriptions, and whether the drugs tested allow identification
of cross-reactors. Methodological variations such as differential
activation times (range 20–40min) and different activation
markers (CD63 and/or CD203c) additionally complicate
comparability of results.
One key question is why should basophils degranulate in an
IgE-dependent fashion in vitro upon stimulation with a dilution
of monomeric small antibiotic haptens? One theory is that the
beta-lactam ring confers instability to the compound facilitating
the conjugation of the drug to abundant blood proteins such
as albumin, transferrin and/or immunoglobulins (Torres et al.,
2016). Once attached to a carrier protein the side chain of the
drug, the thiazolidine ring, or the conjugation site itself are
immunogenic in susceptible individuals and capable of both,
eliciting an IgE response and crosslinking of surface-bound IgE.
Beyond diagnostic purposes one important application of BAT
is determining an IgE-mediated pathomechanism when drug-
specific IgE cannot be evidenced. Wortmannin, for instance, is
a strong inhibitor of phosphatidylinositol 3-kinase (PI3K) and
inhibits basophil activation in response to FcεRI crosslinking
but not to stimulation with fMLF. In patients with selective
allergy to the beta-lactamase inhibitor clavulanic acid, presence of
drug-specific IgE was suspected but not detected. Using BAT an
IgE-mediated pathomechanism was confirmed as BAT became
negative upon stimulation with clavulanic acid in presence of
wortmannin (Torres et al., 2010b).
BAT may be useful also in the diagnosis of immediate
hypersensitivity reactions to quinolones. Diagnosis of quinolone
allergy mainly relies on patient history and clinical manifestation.
Skin tests are hampered by false positive reactions due to skin
irritation rendering the positive predictive value of skin testing
close to chance results. Drug-specific IgE have been reported,
however, validated assays do not exist (Manfredi et al., 2004;
Aranda et al., 2011; Mayorga et al., 2013). Aranda et al. showed
both drug-specific IgE and dose-responsiveness in BAT for
ciprofloxacin, moxifloxacin and levofloxacin, and inhibition of
BAT positivity with wortmannin (Aranda et al., 2011). Moreover,
they reported a higher sensitivity of BAT compared to IgE
testing. Two out of seven studies evaluating BAT in quinolone
hypersensitivity were negative with 0% sensitivity (Seitz et al.,
2009; Lobera et al., 2010). The patient collectives of these two
studies were quite small though as only 6, respectively, 4 patients
were included. Contrary, Rouzaire et al. (2012) tested 34 patients
and reported a very good negative predictive value of BAT
as quinolones were successfully reintroduced in 15 of the 17
patients (50%) who tested negative in BAT. They emphasized the
importance of negative BAT results in quinolone hypersensitivity
as criteria for provocation test and thus the opportunity to
possibly and safely reintroduce the drug (Rouzaire et al., 2012).
Photodegradation could be one cause for false negative results.
This was shown for moxifloxacin as positive results doubled
when BAT was performed in the dark (Mayorga et al., 2013).
Taken together, BAT appears helpful in the management of
fluoroquinolone hypersensitivity.
Basophil Activation in Neuromuscular
Blocking Agent Hypersensitivity
Anaphylactic episodes during general anesthesia have severe
implications for the patient. Neuromuscular blocking agents
(NMBAs) including rocuronium, vecuronium, atracurium,
cisatracurium, and suxamethonium account for >60% of such
cases with a high degree of cross-reactivity within this drug
group and even further to opioid antitussives such as codeine or
morphine, with the existence of drug-specific IgE demonstrated
(Baldo and Fisher, 1983; Vervloet et al., 1983; Sainte-Laudy
et al., 2006; Ebo et al., 2007; Leysen et al., 2013). However, it
has been recognized that IgE accounts for immediate DHRs
against NMBAs only in ∼50% of cases. Therefore, a number
of studies evaluated BAT protocols aiming at a more reliable
before-hand screening tool (Monneret et al., 2000, 2002; Sudheer
et al., 2005; Ebo et al., 2006; Kvedariene et al., 2006; Sudheer
and Appadurai, 2007). Sudheer et al. (2005) compared CD63,
CD203c, histamine release and skin testing for their predictive
values. While specificities reached 100%, the sensitivities of these
four techniques determined for the whole NMBA group in
their cohort of 21 patients resulted in 79, 36, 36, and 64%,
respectively. Other studies reported specificities for BAT based
on CD63 expression of >93% with sensitivities of >54%. As
CD63 enables a better judgment of the type of basophil activation
than CD203c, i.e., creating a log-shift in the flow cytometric
dot plots, Ebo et al. (2006) were able to reach a sensitivity
for DHR against rocuronium >91.7% using 0.5mg/ml of drug
and setting the diagnostic threshold value at 4% to be most
discriminative, as they determined from two-graph receiver
operating characteristics. In a large study involving thorough
diagnostic workup of 104 patients the same group (Leysen et al.,
2011) obtained a positive predictive value of 98% for rocuronium
using the combination of skin testing, BAT, and drug-specific
IgE testing by ImmunoCAP. In their study, skin tests turned out
most reliable, however, when these are negative, BAT is indicated.
For assessment of cross-reactivity between rocuronium and
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vecuronium, the two most often used NMBAs, BAT was found
to complement skin tests well.
Basophil Activation in Radiocontrast Media
Hypersensitivity
Immediate DHRs against non-ionic radiocontrast media (RCM)
occur in 0.7–3.1% of patients, with ionic RCM being even more
prevalent, i.e., up to 12.7% including mild reactions or reactions
due to rapid intravenous infusion of these highly osmolar
substances (Stellato et al., 1996). Nevertheless, 0.04% of patients
experience severe reactions upon administration of non-ionic
RCM (Wolf et al., 1989; Katayama et al., 1990; Lieberman and
Seigle, 1999). Traditionally, RCM reactions have been considered
as non-IgE-mediated, and the majority of DHRs indeed seem to
result from RCM non-specifically binding to surface receptors
or indirectly interfering with the complement or kinin cascades,
but skin testing and BAT have been successfully applied more
recently (Brockow et al., 2009; Javaloyes et al., 2012; Philipse
et al., 2013). Still few anecdotal reports on RCM-specific IgE exist,
therefore, some studies have sought to differentiate IgE- from
non-IgE-mediated mechanisms, however, have not determined
the presence of drug-specific IgE themselves. Moreover, a
number of studies have evaluated BAT as a diagnostic tool
for RCM hypersensitivity, however, giving variable experimental
details, which makes it difficult to judge the mode of basophil
activation (Trcka et al., 2008; Bohm et al., 2011; Pinnobphun
et al., 2011; Salas et al., 2013). Presence of drug-specific IgE was
not shown in any of the reports. Some studies demonstrated log-
shift activation of CD63 (Pinnobphun et al., 2011), while others
did not (Bohm et al., 2011). Meta-analyzing the presented flow
cytometric data some degree of inconsistency in the basophil
activation profiles seems to be a common characteristic of
immediate DHRs against RCM. Other influences may account
as listed in a commentary by Chirumbolo (2013). For instance,
a dose-dependent enhancement of CD63 expression upon pre-
stimulation with interleukin 1β was observed by Boehm et al.,
however, the authors also reported variation of this effect
between different RCM. Summarizing, one can say literature
has demonstrated sensitivities of 46–63% and specificities of
89–100% for BAT qualified on the combination of skin and
provocation testing serving as the current diagnostic standard
for RCM hypersensitivity. In general, good correlation between
skin test, drug provocation test, and BAT has proven useful
to complement in vivo testing (Pinnobphun et al., 2011; Salas
et al., 2013). Nevertheless, only in rare cases drug-specific IgE is
involved.
Basophil Activation in Platinum-Containing
Chemotherapeutic Hypersensitivity
The DHRs against carboplatin or cisplatin, compounds used
repeatedly at high doses in anti-cancer therapy, include hyper-
or hypotension, vomiting, dyspnea, and wheezing. They arise in
up to 26.7% of patients and skin testing has been successfully
performed although safety concerns exist regarding severe side-
effects for the patient and risk of exposure of the medical
personnel (Markman et al., 1999; Leguy-Seguin et al., 2007;
Sugimoto et al., 2011). Consequently, the potential of BAT for
predicting DHRs has been investigated using flow cytometric
determination of CD203c (Iwamoto et al., 2012, 2014). These
authors verified the involvement of IgE in carboplatin-induced
DHR, as the basophil activation could be inhibited by
wortmannin and anti-IgE pretreatment by omalizumab. In a
case study of a severely anaphylactic history, BAT was applied
evaluating the potential additive histamine-liberating effect by
cisplatin following RCM administration (Viardot-Helmer et al.,
2008). In conclusion, a similar situation to RCM seems to occur
with platinum-containing anti-neoplastic drugs. In a low number
of patients drug-specific IgE seems to be involved, still BAT
may be suitable for diagnosis of severe immediate DHRs even
if pharmacologic, i.e., non-immune-mediated mechanisms are
underlying.
Basophil Activation in Analgesic
Hypersensitivity
Non-steroidal anti-inflammatory drugs (NSAIDs) are known
to frequently cause drug hypersensitivity reactions ranging
from mild symptoms, e.g., skin reactions, to severe life-
threatening systemic complications (Kowalski et al., 2011).
Although the symptoms can mimic typical IgE-mediated
reactions, drug-specific IgE seems not to be involved in most
NSAID hypersensitivities, as NSAID-specific IgE has only been
detected for PP (Himly et al., 2003). Investigating severe
selective diclofenac (DF) hypersensitivity using drug-human
serum albumin conjugates of DF and the most common DF
metabolites no drug-specific IgE was detectable by ELISA
(Harrer et al., 2010). Instead of an IgE-mediated mechanism
underlying immediate DHRs to DF, it has been hypothesized
that the inhibition of cyclooxygenase-1, triggering the reduction
of prostaglandin E2 accompanied by an increase in leukotriene
production, accounts for the observed type I-like symptomatic
(Mastalerz et al., 2004). Regardless the lack of NSAID-specific
IgE, BAT has been explored by several groups leading to
conflicting results (Gamboa et al., 2003a, 2004b; Celik et al., 2009;
Gomez et al., 2009; Sanz et al., 2005; Malbran et al., 2007; Bavbek
et al., 2009; Harrer et al., 2010; Korosec et al., 2011; Steiner et al.,
2011; Abuaf et al., 2012; Kim and Cho, 2012; Hagau et al., 2013;
Phillips-Angles et al., 2016). Sensitivities varied from 0 (Harrer
et al., 2010; Steiner et al., 2011) to 80% (Korosec et al., 2011)
and specificities from 40 (Celik et al., 2009) to 100% (Gamboa
et al., 2003a, 2004b; Hagau et al., 2013). Reasons may be manifold
as single NSAIDs and different combinations of NSAIDs were
tested and activation times ranged from 15min to 3 h. In contrast
to the negative BAT results, a most recent case report showed
that basophils of an etoricoxib-hypersensitive patient were tested
positive upon stimulation with the parent drug, although the
authors excluded an involvement of drug specific IgE (Phillips-
Angles et al., 2016). Here and in most other studies CD63 was the
most commonly used activationmarker. Introduction of CD203c
by some groups (Bavbek et al., 2009; Celik et al., 2009; Abuaf
et al., 2012) did not make results less ambiguous. Korosec et al.
(2011) pointed out that a considerate pre-selection of most severe
cases of DHRs may lead to an improvement in sensitivity and
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specificity of BAT. Another important factor for investigating
NSAID hypersensitivity may be the time interval between the
incident and BATwhich should be less than 18 months according
to the EAACI position paper on BAT (Hoffmann et al., 2015)
or less than 6 months according to Gomez et al. (2009).
To put it all in a nutshell, due to the many contradictory
data regarding sensitivity and specificity, potentially resulting
from differences in gating protocols influencing basophil
activation (Chirumbolo, 2014), further large-scale trials following
harmonized BAT protocols including data interpretation are
needed to determine suitability of BAT for diagnosis of NSAID
hypersensitivity.
Basophil Activation in Hypersensitivity to
Other Drugs and Some Remarks on
Biologicals
Various other drugs causing immediate DHRs have been
tested using BAT including atropine (Cabrera-Freitag et al.,
2009), glatiramer acetate (Soriano Gomis et al., 2012),
methylprednisolone (Aranda et al., 2010; Ben Said et al.,
2010a), omeprazole (Gamboa et al., 2003b), the diuretic
hydrochlorothiazide (Gamboa et al., 2005; Manso et al., 2010),
or antihistamines (Caceres Calle and Fernandez-Benitez, 2004;
Bobadilla-Gonzalez et al., 2011; Lee et al., 2011; Sanchez Morillas
et al., 2011) to name a few. However, these reports, most of
them case studies, are hard to judge from the perspective of
validating BAT performance, as no experimental details were
presented. Aranda et al. (2010) showed log-shifts in CD63
expression in the dot plots and indicated involvement of
methylprednisolone-specific IgE as activation could be inhibited
by wortmannin. Accordingly, Soriano Gomis et al. (2012)
determined drug-specific IgE in their workup, however, no
details on how BAT was conducted were given. Unequivocal
BAT performance with 100% sensitivity and 87.5% specificity
evidenced by log-shifts in CD63 expression shown in dot plots
was reported for Gelofusine R© hypersensitivity of 6 patients
(Apostolou et al., 2006).
Adverse reactions to biologicals are increasing due to their
expanding utilization, as reviewed recently (Corominas et al.,
2014; Galvao and Castells, 2015). For instance, rituximab
hypersensitivity with an incidence of 5–10% has been evaluated
using BAT in a cohort of 18 B cell lymphoma patients (Piva
et al., 2012). The authors reported successful discrimination
between patients and controls based on CD63 expression at
in vivo concentrations, however, no experimental details were
presented. Very recently an interesting new approach to predict
DHRs against cetuximab during cancer immunotherapy based
on evaluating the decrease in cetuximab molecules on basophils
after dissociation of IgE from FcεRI was reported (Iwamoto et al.,
2016).
Notably, Werner J. Pichler has proposed a new classification
for biologicals in five classes (α-ε), as biologicals differ in that they
represent intact antigens themselves and are not metabolized like
small molecular weight drugs (Pichler, 2006). We will thus not
discuss ADRs against biologicals here.
CONCLUSIONS
Immediate DHRs present a complex phenomenon in regard
to etiology. Similar clinical phenotypes are observed in “type
I DHRs” with—according to the (pro-)hapten concept—drug-
specific IgE against e.g., antibiotics, half of NMBAs, PP, or
biologicals, and in “type I-like DHRs” elicited by alternative
activation pathways as it is most likely the case with
the other half of NMBAs, most RCM, platinum-containing
chemotherapeutics, or NSAIDs. A close look on the CD63
upregulation pattern may help differentiating, as in type I
DHRs the sudden basophil degranulation usually results in
a log-shift of signal intensity. In contrast, no unequivocal
conclusions on the underlying mechanism may be drawn when
a “smear-like” CD63 upregulation is observed. In such cases,
especially if basophil activation is weak, type I-like mechanisms
independent of IgE cannot be excluded but bear the risk
of false positive interpretation. We, therefore, recommend
inclusion of plots/histograms in the publications to allow the
reader evaluating the basophil activation profile. To circumvent
bystander effects caused by interaction with other cells basophil
purification protocols, as described recently (Steiner et al., 2016),
may be considered, in particular when investigatingmore specific
questions beyond diagnosis. Overall, the basophil response in
BAT is influenced by many so far unpredictable factors which
may impair the quality of results in certain cases (Chirumbolo,
2016).
Finally, we shall not forget that basophil activation test is
an in vitro surrogate marker for a systemic reaction of the
entire organism. This renders skin and/or provocation testing
still of primary importance for diagnosis. Nevertheless, BAT has
qualified a safe and suitable in vitro complement of in vivo testing
in immediate DHRs, as most recently pointed out by a position
paper of the European Network for Drug Allergy (ENDA) and
the EAACI Drug Allergy Interest Group (Mayorga et al., 2016).
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